Status
Conditions
Treatments
Study type
Funder types
Identifiers
About
This study is a pragmatic randomized controlled pilot clinical trial aimed at evaluating the efficacy and safety of herbal medicine treatment strategy for patients with post-traffic accident fatigue, using an education-only group as the control.
Full description
0. Background Over three million traffic accidents occur annually across OECD countries, often resulting in fatigue, insomnia, and dizziness that persist beyond the acute phase. Post-accident fatigue is common even after mild injuries and can greatly hinder recovery and daily functioning. In Korean traditional medicine, it is viewed as a deficiency of qi and blood, for which herbal medicine treatment is used to restore vitality. This study aims to assess whether combining herbal medicine with education improves post-accident fatigue and to explore related body composition changes.
1. Patient Recruitment and Screening Phase
2. Treatment and Evaluation Phase
Control and Experimental Groups
- The test group will be divided into the "medicinal herbal medicine group," and the control group will be the "education-only group."
- To study the additional effects of herbal medicine treatment while maintaining the same conditions for both groups, both groups will receive educational brochures as follows:
Study Duration and Observation Points
- The study period for the subjects will be 12 weeks, including a 4-week treatment period and an 8-week follow-up period.
Data Collection for Evaluation i. Primary Outcome
- (1) FSS-K (Fatigue Severity Scale - Korean version)
- The primary outcome is the FSS-K at Week 5, the end of the treatment intervention.
- The assessment will be conducted at screening, enrollment, and assignment, Weeks 1 and 3 of the treatment period, and at follow-up visits at Weeks 5, 8, and 12.
ii. Secondary Outcome
- The following indicators will be assessed at visits during the treatment period (Weeks 1 and 3) and at follow-up visits (Weeks 5 (primary endpoint), 8, and 12).
- (1) CFQ-K (Chalder Fatigue Questionnaire - Korean version)
- (2) ISI-K (Insomnia Severity Index - Korean version)
- (3) K-BDI (Beck Depression Inventory - Korean version)
- (4) Quality of Life Assessment Scale (EQ-5D-5L)
- (5) Body Fat Percentage
(6) Skeletal Muscle Mass
(7) Phase Angle
(8) Extracellular Water Ratio
(9) Adherence
(10) Adverse Effects
3. Follow-Up Phase After the 4-week treatment period, the subjects will be followed up for 8 weeks to assess symptom changes. Both groups will undergo follow-up visits at 5, 8, and 12 weeks from the date of enrollment, assessing the primary outcome (FSS-K), secondary outcomes (CFQ-K, ISI-K, K-BDI, EQ-5D-5L, body fat percentage, skeletal muscle mass, phase angle, extracellular water content, and medication compliance), and adverse events, identical to those observed during the treatment period.
The follow-up period after 5 weeks will have a time window of ±5 days. The follow-up period after 8 and 12 weeks will have a time window of ±7 days.
Both groups will undergo blood tests at 5 weeks from the date of enrollment. The blood test items will be identical to those used during the screening period.
4. Monitoring The principal investigator or a co-investigator with medical judgment, authorized by the principal investigator, will maintain the integrity of the research data and collect and review safety data for the study subjects. Monitoring will be conducted every six months.
Enrollment
Sex
Ages
Volunteers
Inclusion criteria
Exclusion criteria
Primary purpose
Allocation
Interventional model
Masking
40 participants in 2 patient groups
Loading...
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal